Professional Documents
Culture Documents
Biomarker Qualification Program - FDA
Biomarker Qualification Program - FDA
February 22, 2024: Biomarker-driven Drug Development for Allergic Diseases and Asthma (/news-
events/fda-meetings-conferences-and-workshops/biomarker-driven-drug-development-allergic-
diseases-and-asthma-public-workshop-02222024)
To locate a project or a qualified biomarker go to CDER & CBER’s DDT Qualification Project Search
database (https://fda.force.com/ddt/s/) (http://www.fda.gov/about-fda/website-policies/website-
disclaimer)
Web content is updated for consistency with 21st Century Cures Act (/drugs/drug-development-tools-
qualification-programs/21st-century-cures-act-qualification-drug-development-tools)!
MISSION
The mission of the CDER Biomarker Qualification Program (BQP) is to work with external stakeholders
to develop biomarkers as drug development tools. Qualified biomarkers have the potential to advance
public health by encouraging efficiencies and innovation in drug development.
Top ()
https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/biomarker-qualification-program 1/3
2/1/24, 8:02 PM Biomarker Qualification Program | FDA
Transcript (/drugs/biomarker-qualification-program/transcript-about-fdas-biomarker-qualification-
program)
GOALS
Support outreach to stakeholders for the identification and development of new biomarkers
Provide a framework for the review of biomarkers for use in regulatory decision-making
Qualify biomarkers for specific contexts of use that address specified drug development needs
Additional Information
https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/biomarker-qualification-program 2/3
2/1/24, 8:02 PM Biomarker Qualification Program | FDA
Top ()
https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/biomarker-qualification-program 3/3